Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy.

Suppr

超能文献

作者信息

Ishimura E, Nishizawa Y, Emoto M, Shoji T, Inaba M, Kawagishi T, Morii H

出版信息

Nephron. 1997;76(2):227-9. doi: 10.1159/000190175.

DOI:10.1159/000190175

PMID:9200418

Abstract

摘要

相似文献

Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy.

Nephron. 1997;76(2):227-9. doi: 10.1159/000190175.

Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.

Diabetes Res Clin Pract. 2002 Nov;58(2):123-9. doi: 10.1016/s0168-8227(02)00105-5.

Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.

Clin Exp Nephrol. 2008 Apr;12(2):119-125. doi: 10.1007/s10157-007-0011-8. Epub 2008 Jan 5.

Effects of sarpogrelate on microvascular complications with type 2 diabetes.

Int J Clin Pharm. 2019 Apr;41(2):563-573. doi: 10.1007/s11096-019-00794-7. Epub 2019 Mar 12.

Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.

Cerebrovasc Dis. 2007;24(2-3):264-70. doi: 10.1159/000105135. Epub 2007 Jul 4.

[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain].

Nihon Rinsho. 2001 Sep;59(9):1675-80.

Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.

J Cardiovasc Pharmacol. 2007 Apr;49(4):221-7. doi: 10.1097/FJC.0b013e3180325af3.

Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.

Spine (Phila Pa 1976). 2007 Feb 1;32(3):315-20. doi: 10.1097/01.brs.0000253601.35732.c1.

Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.

PLoS One. 2017 Jun 22;12(6):e0179221. doi: 10.1371/journal.pone.0179221. eCollection 2017.

Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.

Vasc Med. 2006 May;11(2):75-83. doi: 10.1191/1358863x06vm657oa.

引用本文的文献

Modality selective roles of pro-nociceptive spinal 5-HT and 5-HT receptors in normal and neuropathic states.

Neuropharmacology. 2018 Dec;143:29-37. doi: 10.1016/j.neuropharm.2018.09.028. Epub 2018 Sep 18.

The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.

Trials. 2010 Dec 20;11:122. doi: 10.1186/1745-6215-11-122.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验